Celastrol targets VDAC2 to induce mitochondria-dependent ferroptosis and apoptosis in hepatocellular carcinoma, with liposome-based delivery enhancing its efficacy and reducing side effects. This evidence concerns the gene VDAC2 and hepatocellular carcinoma.